News Summary

Eli Lilly, a major pharmaceutical company, has initiated legal action against four telehealth startups—Mochi Health, Fella & Delilah Health, Willow Health, and Henry Meds. These companies are accused of selling compounded versions of tirzepatide, the active ingredient in Lilly’s diabetes and obesity drugs, Mounjaro and Zepbound. The lawsuit is part of an ongoing struggle between the pharmaceutical industry and healthcare providers over the production of affordable, off-brand versions of popular drugs. The telehealth companies claim their compounded medications are tailored to individual patient needs and are legally prescribed by licensed medical providers. However, these compounded versions are not FDA-approved and are often marketed at a lower cost than the brand-name drugs. The legal action underscores the tension between ensuring drug affordability and protecting pharmaceutical patents.